Feature | Ventricular Assist Devices (VAD) | July 15, 2015

Thoratec Receives CE Mark Approval For HeartMate PHP

Company will begin measured rollout of percutaneous pump with catheter-based hemodynamic support through 2015 and 2016

Thoratec, HeartMate PHP. CE Mark approval, SHIELD I

July 15, 2015 - Thoratec announced that the HeartMate PHP (Percutaneous Heart Pump) received CE Mark approval, permitting sale in the European Union and other international countries. Approval was based on data from the first 30 patients enrolled in the HeartMate PHP SHIELD I CE Mark Trial examining use of PHP to support patients undergoing a high-risk percutaneous coronary intervention (PCI) procedure. Data from all 50 patients enrolled in this study will be presented later in 2015.

HeartMate PHP is an acute cardiac assist device designed to uncouple the traditional relationship between size and flow in catheter-based support devices. The proprietary expandable catheter technology of HeartMate PHP is capable of generating average blood flow of 4-5 liters per minute following delivery through a true percutaneous insertion. The device has been designed for hemocompatibility, with typical operating RPMs of 17,000-20,000. "The SHIELD I clinical experience demonstrated both the performance and ease of use of HeartMate PHP, which was able to safely maintain or improve the hemodynamic profile of severely ill patients undergoing complex revascularizations," said Dariusz Dudek, M.D., the SHIELD I principal investigator and physician in chief, Department of Cardiology and Cardiovascular Interventions at the University Hospital in Krakow, Poland.

The HeartMate PHP European launch will include a measured rollout to targeted countries, staged through the balance of 2015 and 2016. Previously issued company guidance for 2015 financial results included the expected impact of revenue and costs associated with HeartMate PHP and the European launch, with internal resources principally focused on the HeartMate PHP U.S. IDE study. The SHIELD II U.S. IDE trial recently received unconditional approval from the U.S. Food and Drug Administration (FDA) and is still expected to begin enrollment during the third quarter.

For more information: www.thoratec.com

Related Content

Videos | Hemodynamic Support Devices | August 31, 2018
Behnam Tehrani, M.D., FSCAI, director of the cardiac cath lab, INOVA Heart and Vascular Institute, Fairfax, Va., disc
Two versions of the Abiomed Impella percutaneous ventricular assist device being shown at ACC 2018. Impella is the only device currently cleared by the FDA for use in cardiogenic shock.

Two versions of the Abiomed Impella percutaneous ventricular assist device displayed at ACC 2018. Impella is the only device that currently has a FDA indication for use in cardiogenic shock. 

Feature | Hemodynamic Support Devices | July 08, 2018 | Emmanouil S. Brilakis, M.D., Ph.D., FSCAI and Srihari S. Naidu, M.D., FSCAI
Cardiogenic shock (CS) is a low-cardiac-output state resulting in life-threatening end-organ hypoperfusion and hypo
William O'Neill, M.D., unveils the Detroit Cardiogenic Shock Initiative at Henry Ford Hospital. The program uses new protocols to reduce cardiogenic shock mortality by 50 percent by using early hemodyanmic support.

William O'Neill, M.D., unveils the Detroit Cardiogenic Shock Initiative at Henry Ford Hospital. The program uses new protocols to reduce cardiogenic shock mortality by 50 percent by using early hemodyanmic support. 

Feature | Hemodynamic Support Devices | June 22, 2018 | Dave Fornell, Editor
About 50 percent of patients in cardiogenic shock do not survive, and account for about 90,000 heart attack patients
News | Hemodynamic Support Devices | April 12, 2018
French medical technology company CorWave announced it has been awarded almost $3.5 million in financing for its R&...
Abiomed Receives Expanded Impella Approval for Cardiomyopathy With Cardiogenic Shock
News | Hemodynamic Support Devices | February 15, 2018
Abiomed Inc. announced that it received an expanded U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA)...
Abiomed Impella percutaneous ventricular assist device (pVAD) heart pump gains FDA PMA for high risk PCI.
Feature | Hemodynamic Support Devices | February 14, 2018
February 14, 2018 — Abiomed Inc. announced it received an expanded U.S.
Technavio Market Study Shows Donor Shortage and Improved Survival Rate
News | Hemodynamic Support Devices | January 25, 2018
January 25, 2018 – According to the latest market study released by Technavio, the global circulatory support devices
Miracor Medical Raises money for its PiCSO therapy used during stenting procedures in acute myocardial infarct (AMI) to intermittently increase pressure in the coronary venous system.
News | Hemodynamic Support Devices | January 16, 2018
Miracor Medical Systems GmbH (Miracor Austria) and Miracor Medical SA (Miracor Medical) announced the closing of €25m...
Overlay Init